Revisión sistemática de datos farmacoeconómicos de los tratamientos triples y cuádruples para la erradicación de Helicobacter pylori.

Abstract

The objective of the research project was to carry out a systematic review of the scientific literature on pharmacoeconomic data related to triple and quadruple treatments for the eradication of Helicobacter pylori. A systematic review of the NLM, Science Direct and Cochrane databases was carried out in the period January 2010 - August 2020. The search energy consisted of identifying the key concepts in Medical Subject Headings (MeSH), these being “Helicobacter pylori”, "Costs and Costs analyzes", "Economics, Pharmaceutical", "Drugs theraphy", "Health Care Cost", "Peptic Ulcers", "Proton Pump Inhibitors", "Anti bacterial Agents", "Dyspepsias", "Disease Eradication" and Bismuth tripotassium dicitrate ”. This allowed searching the concepts from the most general to the most restricted terms (explosion frequency) in the chapters and abstracts indexed in the information sources. The PRISMA methodology was applied in the Covidence software. The data to analyze correspond to history of resistance, diagnostic method, detail of pharmacological therapy, pharmacological regimen, administration time, method of evaluation of the eradication of infection, effectiveness of the regimen, p-value, cost of individual drug treatment in dollars. Twenty-five scientific articles were included in this review, the total of pharmacological alternatives (n = 65), 25 first-line triple therapy alternatives and 5 second-line triple therapy alternatives, 28 first-line quadruple therapy alternatives were reported , 6 second-line quadruple therapy alternatives and 1 third-line quadruple therapy alternative. 24% of the total triple therapies are effective, 71% of the total quadruple therapies reached the effectiveness superior to 90%. If there is an impact between the effectiveness of drug therapy and treatment costs. It is recommended to prioritize pharmacoeconomic studies in order to obtain information and establish a historical precedent for investment in drug therapy in patients with Helicobacter pylori.